Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor

NCT01571076 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2021-01-19

No results posted yet for this study

Summary

Preimplantation Genetic Screening (PGS) is used for the selection of chromosomally normal embryos before the transfer in IVF treatments in many cases. There is great debate in the scientific community as to whether this is an efficient practice in patients of different prognosis.

This prospective and randomized study seeks to study the results of chromosomal diagnosis using the new Comparative Genomic hybridization (CGH) arrays technique by practicing Preimplantation Genetic Screening (PGS) in day three biopsy on one arm of the study and not on the other arm in order to compare the results. The investigators will study the ongoing pregnancy rate of each oocyte retrieval and the ongoing implantation rate with Day 5 embryos (blastocysts) in IVF/ intracytoplasmic sperm injection (ICSI) treatments of embryos from two different groups of patients: Advanced Age Female Patients (38 - 41 years of age) and Male severe factor (≥2 million spermatozoids/ml.).

Conditions

Interventions

GENETIC

PGS

Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.

GENETIC

PGS

Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.

OTHER

Prolonged culture

The embryos will be in prolonged culture and on going embryos transferred on Day 5 .

OTHER

Prolonged culture

Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.

Sponsors & Collaborators

  • Igenomix

    lead INDUSTRY

Principal Investigators

  • Carlos Simon, MDPhD · Director

  • Carmen Rubio, PhD · Igenomix

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-09-30
Completion
2015-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01571076 on ClinicalTrials.gov